Targetable drivers in non-small cell lung cancer include ALK, RET, and ROS1 fusions—do you know how to detect them? DNA-based and RNA-based sequencing each have advantages and drawbacks when it comes to fusion detection. In this webinar, expert speakers will present their perspectives on fusion detection using next-generation sequencing in NSCLC.
Targetable drivers in non-small cell lung cancer include ALK, RET, and ROS1 fusions—do you know how to detect them? DNA-based and RNA-based sequencing each have advantages and drawbacks when it comes to fusion detection. In this webinar, expert speakers will present their perspectives on fusion detection using next-generation sequencing in NSCLC.
Targetable drivers in non-small cell lung cancer include ALK, RET, and ROS1 fusions—do you know how to detect them? DNA-based and RNA-based sequencing each have advantages and drawbacks when it comes to fusion detection. In this webinar, expert speakers will present their perspectives on fusion detection using next-generation sequencing in NSCLC.
Targetable drivers in non-small cell lung cancer include ALK, RET, and ROS1 fusions—do you know how to detect them? DNA-based and RNA-based sequencing each have advantages and drawbacks when it comes to fusion detection. In this webinar, expert speakers will present their perspectives on fusion detection using next-generation sequencing in NSCLC.
Join AdventHealth Cancer Institute for our 11th annual licensed Best of ASCO® meeting, bringing the best of the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held at The JW Marriott Orlando, Grande Lakes in Orlando, Florida. Each year, the ASCO® scientific committee selects the highest-rated abstracts from the ASCO® Annual Meeting to be available for licensed…
